

# THERANOSTICS AND NUCLEAR MEDICINE DEPARTMENT

St Vincent's Hospital Sydney Ltd Level 2, 390 Victoria Street Darlinghurst NSW 2010 P: (02) 8382 1830 F: (02) 8382 1824 E: svhs.nm@svha.org.au www.stvincents.com.au

**APPOINTMENT** 

Date

Time

## PET/CT PATIENT REQUEST

Director:	PATIENT DETAILS									
A/Prof Louise Emmett	Full Name:						DOB:			
	Address:									
Consultants:										
Dr Chan	Contact Number:						MRN:			
Dr Ho										
A/Prof Pocock	Indication* - Please tick appropriate box *See reverse for more detailed description of indications									
Dr Nguyen	MALIGNA	MALIGNANT BRAIN TUMOUR					HODGKIN'S (HL) or NON-HODGKIN'S LYMPHOMA (NHL) Initial staging Initial staging of indolent NHL Restaging following recurrence confirmation Assess response to second line chemotherapy			
Dr Lee	HEAD & NECK CANCER Staging									
	Evaluation									
Dr Liu	METASTATIC SCC in cervical nodes of unknown primary						Assess response of residual mass to first line therapy either during treatment or within 3 months completing definitive first line treatment			
	OESOPHAGEAL or GASTRO-OESOPHAGEAL JUNCTION									
	SOLITARY PULMONARY NODULE						SARCOMA			
	NON-SMALL CELL LUNG CANCER						Initial staging Suspected residual or recurrent			
	COLORECTAL CARCINOMA						MALIGNANT MELANOMA			
	OVARIAN CARCINOMA						CARDIAC SARCOID (UNFUNDED)			
	UTERINE				CANCER		F18 BONE S	CAN / OTHE	R:	
		mary staging ging for local recurrence	urrence	Staging Evaluatio	ın					
							Unfunded (No Medicare Item Number)			
	CLINICAL HISTORY									
	Primary Site: <u>Pre</u> -PET Sta					Stage	: T N	M		
	Suspected/known metastases: Ye			s No Date:			Where:			
	Histology/Biopsy: Yes			No Date:			Where:			
	Prior Relative Imaging: Yes No Date:						Where:			
	Diabetic: Yes No Type:									
	Last Radiation Therapy Treatment Date:  *Recent treatment may interfere with interpretation  Last Chemotherapy Treatment Date:  *Recent treatment may interfere with interpretation									
	Additional Clinical History: (e.g. recent infections, treatment or surgical findings)									
	ADDITIONAL DIAGNOSTIC CT IF REQUIRED: Yes No eGFR: Creatinine: Date: Please fax kidney function blood tests									
	Area:	Brain	Neck	Chest		Abdo	men Pe	elvis		
	REFERRING DOCTOR									
		2001011								
	Signature:						Date:			
		RESULTS:	Routine	Urge	ent		PROVID	E: Film	CD/USB	



Below is a detailed list of the rebates available from Medicare. Please ensure that one box is ticked on the front page of the request form. If you have any questions regarding funding for a PET/CT scan, please call (02) 8382 1830.

## Indication

#### **MALIGNANT BRAIN TUMOUR**

Suspected residual or recurrent after definitive therapy to guide biopsy and to assist in treatment planning for further active therapy

## **HEAD & NECK CANCER**

- Staging of biopsy proven, newly diagnosed or recurrent
- Suspected residual after definitive treatment and suitable for active therapy

METASTATIC SCC in cervical nodes of unknown primary

OESOPHAGEAL or GASTRO-OESOPHAGEAL JUNCTION CARCINOMA in patients suitable for active therapy

SOLITARY PULMONARY NODULE unsuitable for transthoracic biopsy or failed attempt at pathological characteristation

NON-SMALL CELL LUNG CANCER where curative surgery or radiotherapy is planned

COLORECTAL CARCINOMA suspected residual or recurrence in patients suitable for active therapy

OVARIAN CARCINOMA evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients suitable for active therapy

#### **UTERINE CERVIX**

- Further primary staging of proven carcinoma, at FIGO stage IB2 or greater, prior to radiation therapy or combined modality therapy
- Further staging for local recurrence considered suitable for therapy with curative intent

## HODGKIN'S (HL) or NON-HODGKIN'S LYMPHOMA (NHL)

- Initial staging of newly diagnosed or previously untreated (excluding indolent NHL)
- For initial staging of indolent NHL if findings indicate stage I or IIA and radiotherapy for curative intent is planned
- Restaging following recurrence confirmation (excluding indolent NHL)
- Assess response to second line chemotherapy when stem cell transplantation is considered (excluding indolent NHL)
- Assess response of residual mass to first line therapy either during treatment or within 3 months completing definitive first line treatment (excluding indolent NHL)

#### **SARCOMA**

- Initial staging of biopsy proven bone or soft tissue, considered potentially curable by conventional staging (excluding GIST)
- Suspected residual or recurrent after initial course of definitive therapy or during chemotherapy (excluding GIST)

MALIGNANT MELANOMA suspected metastasis or recurrence in patients suitable for active therapy

## **BREAST CANCER**


- Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy
- Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy

## **Unfunded (No Medicare Item Number)**

Please confirm pricing at booking. All charges need to be payable on the day and patients must be made aware of the cost by their referring specialist.

## **CAR PARKING**

Parking is available in the hospital parking station (fees apply), entry via Victoria Street. There is also limited metered parking in surrounding streets.



## **PUBLIC TRANSPORT**

## BUS

Routes 378 and 311 (from Railway Square) and 380 and 389 (from Circular Quay).

## TRAIN

The closest train station is Kings Cross on the Eastern Suburbs Line, a 15 minute walk along Victoria Street.

## VILLAGE TO VILLAGE, A FREE BUS SERVICE

This service enables all residents of the City of Sydney to access local amenities and stops directly outside St Vincent's Public Hospital on Thursdays and Fridays.

## TAX

Taxis regularly service St Vincent's Hospital.

Theranostics and Nuclear Medicine Department, Level 2, 390 Victoria Street, Darlinghurst NSW 2010